Compounds > kaf156
Page last updated: 2024-11-13

kaf156

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ganaplacide: antimalarial [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID49856296
CHEMBL ID2058833
SCHEMBL ID1047381
MeSH IDM000608344

Synonyms (35)

Synonym
bdbm50388532
ganaplacide
gnf-156
kaf 156
gnf 156
CHEMBL2058833 ,
kaf-156
kaf156
2-amino-1-[3-(4-fluoroanilino)-2-(4-fluorophenyl)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7-yl]ethanone
SCHEMBL1047381
1261113-96-5
ganaplacide [who-dd]
2-amino-1-(2-(4-fluorophenyl)-3-((4-fluorophenyl)amino)-5,6-dihydro-8,8-dimethylimidazo(1,2-a)pyrazin-7(8h)-yl)ethanone
ganaplacide [inn]
ethanone, 2-amino-1-(2-(4-fluorophenyl)-3-((4-fluorophenyl)amino)-5,6-dihydro-8,8-dimethylimidazo(1,2-a)pyrazin-7(8h)-yl)-
85VMN9JU7A ,
AKOS030629999
unii-85vmn9ju7a
H11185
2-amino-1-(2-(4-fluorophenyl)-3-((4-fluorophenyl)amino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)ethanone
kaf 156; kaf156; gnf-156; gnf156; gnf 156; ganaplacide
BCP21186
Q28209255
mfcd28502124
2-amino-1-[2-(4-fluorophenyl)-3-[(4-fluorophenyl)amino]-5,6-dihydro-8,8-dimethylimidazo[1,2-a]pyrazin-7(8h)-yl]ethanone
AS-49356
gtpl9946
gnf156
SB17068
A856033
TQR0232
EX-A6670
DTXSID701105307
HY-108024
CS-0027183

Research Excerpts

Overview

KAF156 is a novel antimalarial drug that is active against both liver- and blood-stage Plasmodium parasites, including drug-resistant strains. KAF156 has activity against pre-erythrocytic liver stages, asexual and sexual blood stages.

ExcerptReferenceRelevance
"KAF156 is a novel antimalarial drug that is active against both liver- and blood-stage Plasmodium parasites, including drug-resistant strains. "( Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection Study.
Berger, D; Chang, M; Czartoski, JL; Duke, E; Jain, JP; Kappe, SHI; Kublin, JG; Leong, FJ; Maenza, J; Murphy, SC; Pertel, P; Potochnic, MA; Prince, WT; Seilie, AM; Soon, RL; Spera, D; Vaughan, A; Zhao, R, 2021)		2.3
"KAF156 is a novel imidazolopiperazine anti-malarial with activity against pre-erythrocytic liver stages, asexual and sexual blood stages. "( A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine.
Feng, Y; Goswami, B; Jain, JP; Leong, FJ; Stein, DS, 2018)		2.14

Toxicity

KAF156 was tolerated, with self-limited mild to moderate gastrointestinal and neurological adverse events. KAF156 demonstrated high levels of pre- and post-CHMI protective efficacy.

ExcerptReferenceRelevance
" KAF156 was tolerated, with self-limited mild to moderate gastrointestinal and neurological adverse events."( A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Diagana, TT; Leong, FJ; Magnusson, B; Pertel, P; Zeng, S; Zhao, R, 2014)		1.51
"KAF156 at all dose levels was safe and well tolerated."( Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection Study.
Berger, D; Chang, M; Czartoski, JL; Duke, E; Jain, JP; Kappe, SHI; Kublin, JG; Leong, FJ; Maenza, J; Murphy, SC; Pertel, P; Potochnic, MA; Prince, WT; Seilie, AM; Soon, RL; Spera, D; Vaughan, A; Zhao, R, 2021)		2.3
"KAF156 was safe and well tolerated and demonstrated high levels of pre- and post-CHMI protective efficacy."( Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection Study.
Berger, D; Chang, M; Czartoski, JL; Duke, E; Jain, JP; Kappe, SHI; Kublin, JG; Leong, FJ; Maenza, J; Murphy, SC; Pertel, P; Potochnic, MA; Prince, WT; Seilie, AM; Soon, RL; Spera, D; Vaughan, A; Zhao, R, 2021)		2.3

Pharmacokinetics

This first-in-human, single- and multiple-ascending-dose study in 70 healthy male volunteers determined the maximum oral dose of KAF156 tolerated by healthy adults. Co-administration of PPQ and K AF156 had no overall effect on AUC of either compound, but the Cmax values of both KAF 156 and piperaquine increased.

ExcerptReferenceRelevance
" This first-in-human, single- and multiple-ascending-dose study in 70 healthy male volunteers determined the maximum oral dose of KAF156 tolerated by healthy adults and derived pharmacokinetic data (including preliminary food effect) to enable dose calculations for malaria patients."( A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Diagana, TT; Leong, FJ; Magnusson, B; Pertel, P; Zeng, S; Zhao, R, 2014)		0.81
" Based on in vitro data, a two-way pharmacokinetic interaction was hypothesized for KAF156 use in combination with piperaquine (PPQ) as both drugs are CYP3A4 substrates and inhibitors."( A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine.
Feng, Y; Goswami, B; Jain, JP; Leong, FJ; Stein, DS, 2018)		0.92
" Routine safety and pharmacokinetic assessments were carried out up to 61 days."( A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine.
Feng, Y; Goswami, B; Jain, JP; Leong, FJ; Stein, DS, 2018)		0.7
" Co-administration of PPQ and KAF156 had no overall effect on AUC of either compound, but the Cmax values of both KAF156 (~ 23%) and piperaquine (~ 70%) increased."( A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine.
Feng, Y; Goswami, B; Jain, JP; Leong, FJ; Stein, DS, 2018)		0.99

Dosage Studied

ExcerptRelevanceReference
" The available data suggest that ganaplacide exerts multi-stage antimalarial activity, and that its pharmacokinetic profile potentially allows for a simplified dosing regimen compared to that of existing antimalarial drug combinations."( The  early  preclinical and clinical development of ganaplacide (KAF156), a novel antimalarial compound.
Grobusch, MP; Koller, R; Mombo-Ngoma, G, 2018)		0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (30)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A1Homo sapiens (human)IC50 (µMol)6.00000.00791.24789.9000AID1849707
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)6.00000.00011.774010.0000AID1849707; AID673153
Cytochrome P450 2E1Homo sapiens (human)IC50 (µMol)6.00000.01401.68726.2000AID1849707
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)6.00000.00011.753610.0000AID1849707; AID673157
Cytochrome P450 3A4Homo sapiens (human)Ki0.15600.00011.41629.9000AID1579733
Cytochrome P450 2C8Homo sapiens (human)IC50 (µMol)6.00000.00081.88487.9000AID1849707
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)6.00000.00002.015110.0000AID1849707; AID673156
Cytochrome P450 2A6Homo sapiens (human)IC50 (µMol)6.00000.00443.889510.0000AID1849707
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)6.00000.00002.800510.0000AID1849707; AID673155
Cytochrome P450 4B1Homo sapiens (human)IC50 (µMol)6.00006.20006.20006.2000AID1849707
Cytochrome P450 2B6Homo sapiens (human)IC50 (µMol)6.00000.00113.418610.0000AID1849707
Cytochrome P450 3A5Homo sapiens (human)IC50 (µMol)6.00000.00330.70736.2000AID1849707
Cytochrome P450 2A7Homo sapiens (human)IC50 (µMol)6.00006.20006.20006.2000AID1849707
Cytochrome P450 3A7Homo sapiens (human)IC50 (µMol)6.00000.01402.75806.2000AID1849707
Cytochrome P450 2F1Homo sapiens (human)IC50 (µMol)6.00006.20006.20006.2000AID1849707
Cytochrome P450 2C18Homo sapiens (human)IC50 (µMol)6.00006.20006.20006.2000AID1849707
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)6.00000.00002.398310.0000AID1849707; AID673154
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)6.00000.01202.53129.4700AID1849707
Cytochrome P450 4F2Homo sapiens (human)IC50 (µMol)6.00001.60004.26676.2000AID1849707
Cytochrome P450 4F8Homo sapiens (human)IC50 (µMol)6.00006.20006.20006.2000AID1849707
Cytochrome P450 4A11Homo sapiens (human)IC50 (µMol)6.00006.20006.20006.2000AID1849707
Cytochrome P450 4F3Homo sapiens (human)IC50 (µMol)6.00006.20006.20006.2000AID1849707
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)13.40000.00091.901410.0000AID1849708; AID673130
Cytochrome P450 1B1Homo sapiens (human)IC50 (µMol)6.00000.00130.86969.9000AID1849707
Cytochrome P450 2A13Homo sapiens (human)IC50 (µMol)6.00006.20006.20006.2000AID1849707
Cytochrome P450 4A22Homo sapiens (human)IC50 (µMol)6.00006.20006.20006.2000AID1849707
Vitamin D 25-hydroxylaseHomo sapiens (human)IC50 (µMol)6.00006.20006.20006.2000AID1849707
Cytochrome P450 2U1Homo sapiens (human)IC50 (µMol)6.00006.20006.20006.2000AID1849707
Cytochrome P450 2W1Homo sapiens (human)IC50 (µMol)6.00006.20006.20006.2000AID1849707
Cytochrome P450 2S1Homo sapiens (human)IC50 (µMol)6.00006.20006.20006.2000AID1849707
Cytochrome P450 3A43 Homo sapiens (human)IC50 (µMol)6.00000.01402.75806.2000AID1849707
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (177)

Processvia Protein(s)Taxonomy
cellular response to organic cyclic compoundCytochrome P450 1A1Homo sapiens (human)
response to hypoxiaCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
lipid hydroxylationCytochrome P450 1A1Homo sapiens (human)
fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid metabolic processCytochrome P450 1A1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A1Homo sapiens (human)
amine metabolic processCytochrome P450 1A1Homo sapiens (human)
response to nematodeCytochrome P450 1A1Homo sapiens (human)
response to herbicideCytochrome P450 1A1Homo sapiens (human)
ethylene metabolic processCytochrome P450 1A1Homo sapiens (human)
coumarin metabolic processCytochrome P450 1A1Homo sapiens (human)
flavonoid metabolic processCytochrome P450 1A1Homo sapiens (human)
response to iron(III) ionCytochrome P450 1A1Homo sapiens (human)
insecticide metabolic processCytochrome P450 1A1Homo sapiens (human)
dibenzo-p-dioxin catabolic processCytochrome P450 1A1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
response to foodCytochrome P450 1A1Homo sapiens (human)
response to lipopolysaccharideCytochrome P450 1A1Homo sapiens (human)
response to vitamin ACytochrome P450 1A1Homo sapiens (human)
response to immobilization stressCytochrome P450 1A1Homo sapiens (human)
vitamin D metabolic processCytochrome P450 1A1Homo sapiens (human)
retinol metabolic processCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
9-cis-retinoic acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
camera-type eye developmentCytochrome P450 1A1Homo sapiens (human)
nitric oxide metabolic processCytochrome P450 1A1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1A1Homo sapiens (human)
digestive tract developmentCytochrome P450 1A1Homo sapiens (human)
tissue remodelingCytochrome P450 1A1Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A1Homo sapiens (human)
response to hyperoxiaCytochrome P450 1A1Homo sapiens (human)
maternal process involved in parturitionCytochrome P450 1A1Homo sapiens (human)
hepatocyte differentiationCytochrome P450 1A1Homo sapiens (human)
cellular response to copper ionCytochrome P450 1A1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleCytochrome P450 1A1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1A1Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2E1Homo sapiens (human)
lipid hydroxylationCytochrome P450 2E1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2E1Homo sapiens (human)
steroid metabolic processCytochrome P450 2E1Homo sapiens (human)
response to bacteriumCytochrome P450 2E1Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2E1Homo sapiens (human)
carbon tetrachloride metabolic processCytochrome P450 2E1Homo sapiens (human)
benzene metabolic processCytochrome P450 2E1Homo sapiens (human)
4-nitrophenol metabolic processCytochrome P450 2E1Homo sapiens (human)
halogenated hydrocarbon metabolic processCytochrome P450 2E1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2E1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2E1Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A6Homo sapiens (human)
steroid metabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin catabolic processCytochrome P450 2A6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
fatty acid metabolic processCytochrome P450 4B1Homo sapiens (human)
biphenyl metabolic processCytochrome P450 4B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2B6Homo sapiens (human)
steroid metabolic processCytochrome P450 2B6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2B6Homo sapiens (human)
cellular ketone metabolic processCytochrome P450 2B6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2B6Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A5Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A5Homo sapiens (human)
steroid metabolic processCytochrome P450 3A5Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A5Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A5Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A5Homo sapiens (human)
retinol metabolic processCytochrome P450 3A5Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A5Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A5Homo sapiens (human)
oxidative demethylationCytochrome P450 3A5Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A7Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A7Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A7Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A7Homo sapiens (human)
steroid biosynthetic processCytochrome P450 3A7Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A7Homo sapiens (human)
steroid metabolic processCytochrome P450 3A7Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A7Homo sapiens (human)
retinol metabolic processCytochrome P450 3A7Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A7Homo sapiens (human)
oxidative demethylationCytochrome P450 3A7Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2F1Homo sapiens (human)
response to toxic substanceCytochrome P450 2F1Homo sapiens (human)
naphthalene catabolic processCytochrome P450 2F1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2F1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C18Homo sapiens (human)
retinol metabolic processCytochrome P450 2C18Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C18Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2C18Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C18Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
very long-chain fatty acid metabolic processCytochrome P450 4F2Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 4F2Homo sapiens (human)
renal water homeostasisCytochrome P450 4F2Homo sapiens (human)
pressure natriuresisCytochrome P450 4F2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 4F2Homo sapiens (human)
leukotriene metabolic processCytochrome P450 4F2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 4F2Homo sapiens (human)
blood coagulationCytochrome P450 4F2Homo sapiens (human)
regulation of blood pressureCytochrome P450 4F2Homo sapiens (human)
fatty acid omega-oxidationCytochrome P450 4F2Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 4F2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 4F2Homo sapiens (human)
negative regulation of icosanoid secretionCytochrome P450 4F2Homo sapiens (human)
positive regulation of icosanoid secretionCytochrome P450 4F2Homo sapiens (human)
leukotriene B4 catabolic processCytochrome P450 4F2Homo sapiens (human)
vitamin E metabolic processCytochrome P450 4F2Homo sapiens (human)
menaquinone catabolic processCytochrome P450 4F2Homo sapiens (human)
phylloquinone catabolic processCytochrome P450 4F2Homo sapiens (human)
vitamin K catabolic processCytochrome P450 4F2Homo sapiens (human)
sodium ion homeostasisCytochrome P450 4F2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 4F2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 4F8Homo sapiens (human)
prostaglandin metabolic processCytochrome P450 4F8Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 4A11Homo sapiens (human)
renal water homeostasisCytochrome P450 4A11Homo sapiens (human)
pressure natriuresisCytochrome P450 4A11Homo sapiens (human)
fatty acid metabolic processCytochrome P450 4A11Homo sapiens (human)
leukotriene metabolic processCytochrome P450 4A11Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 4A11Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 4A11Homo sapiens (human)
oxylipin biosynthetic processCytochrome P450 4A11Homo sapiens (human)
positive regulation of icosanoid secretionCytochrome P450 4A11Homo sapiens (human)
leukotriene B4 catabolic processCytochrome P450 4A11Homo sapiens (human)
sodium ion homeostasisCytochrome P450 4A11Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 4A11Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 4A11Homo sapiens (human)
kidney developmentCytochrome P450 4A11Homo sapiens (human)
lauric acid metabolic processCytochrome P450 4A11Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 4A11Homo sapiens (human)
icosanoid metabolic processCytochrome P450 4F3Homo sapiens (human)
leukotriene metabolic processCytochrome P450 4F3Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 4F3Homo sapiens (human)
leukotriene B4 catabolic processCytochrome P450 4F3Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A13Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 2A13Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A13Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A13Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 4A22Homo sapiens (human)
lipid hydroxylationCytochrome P450 4A22Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 4A22Homo sapiens (human)
lauric acid metabolic processCytochrome P450 4A22Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 4A22Homo sapiens (human)
kidney developmentCytochrome P450 4A22Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 4A22Homo sapiens (human)
vitamin metabolic processVitamin D 25-hydroxylaseHomo sapiens (human)
response to cesium ionVitamin D 25-hydroxylaseHomo sapiens (human)
response to ionizing radiationVitamin D 25-hydroxylaseHomo sapiens (human)
calcitriol biosynthetic process from calciolVitamin D 25-hydroxylaseHomo sapiens (human)
vitamin D metabolic processVitamin D 25-hydroxylaseHomo sapiens (human)
xenobiotic metabolic processVitamin D 25-hydroxylaseHomo sapiens (human)
organic acid metabolic processVitamin D 25-hydroxylaseHomo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2U1Homo sapiens (human)
cytochrome metabolic processCytochrome P450 2U1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2U1Homo sapiens (human)
organic acid metabolic processCytochrome P450 2U1Homo sapiens (human)
phospholipid metabolic processCytochrome P450 2W1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2W1Homo sapiens (human)
retinoic acid catabolic processCytochrome P450 2W1Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 2W1Homo sapiens (human)
cytochrome metabolic processCytochrome P450 2W1Homo sapiens (human)
organic acid metabolic processCytochrome P450 2W1Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2S1Homo sapiens (human)
prostaglandin metabolic processCytochrome P450 2S1Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2S1Homo sapiens (human)
cytochrome metabolic processCytochrome P450 2S1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2S1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2S1Homo sapiens (human)
cytochrome metabolic processCytochrome P450 3A43 Homo sapiens (human)
steroid metabolic processCytochrome P450 3A43 Homo sapiens (human)
oxidative demethylationCytochrome P450 3A43 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (78)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
iron ion bindingCytochrome P450 1A1Homo sapiens (human)
protein bindingCytochrome P450 1A1Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activity, acting on diphenols and related substances as donorsCytochrome P450 1A1Homo sapiens (human)
flavonoid 3'-monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxygen bindingCytochrome P450 1A1Homo sapiens (human)
enzyme bindingCytochrome P450 1A1Homo sapiens (human)
heme bindingCytochrome P450 1A1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 1A1Homo sapiens (human)
demethylase activityCytochrome P450 1A1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 1A1Homo sapiens (human)
aromatase activityCytochrome P450 1A1Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 2E1Homo sapiens (human)
iron ion bindingCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activityCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 2E1Homo sapiens (human)
4-nitrophenol 2-monooxygenase activityCytochrome P450 2E1Homo sapiens (human)
oxygen bindingCytochrome P450 2E1Homo sapiens (human)
enzyme bindingCytochrome P450 2E1Homo sapiens (human)
heme bindingCytochrome P450 2E1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 2E1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 2E1Homo sapiens (human)
aromatase activityCytochrome P450 2E1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2E1Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2E1Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2A6Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A6Homo sapiens (human)
enzyme bindingCytochrome P450 2A6Homo sapiens (human)
heme bindingCytochrome P450 2A6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 4B1Homo sapiens (human)
iron ion bindingCytochrome P450 4B1Homo sapiens (human)
oxygen bindingCytochrome P450 4B1Homo sapiens (human)
heme bindingCytochrome P450 4B1Homo sapiens (human)
aromatase activityCytochrome P450 4B1Homo sapiens (human)
heterocyclic compound bindingCytochrome P450 4B1Homo sapiens (human)
monooxygenase activityCytochrome P450 2B6Homo sapiens (human)
iron ion bindingCytochrome P450 2B6Homo sapiens (human)
testosterone 16-alpha-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
heme bindingCytochrome P450 2B6Homo sapiens (human)
testosterone 16-beta-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2B6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2B6Homo sapiens (human)
monooxygenase activityCytochrome P450 3A5Homo sapiens (human)
iron ion bindingCytochrome P450 3A5Homo sapiens (human)
protein bindingCytochrome P450 3A5Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A5Homo sapiens (human)
oxygen bindingCytochrome P450 3A5Homo sapiens (human)
heme bindingCytochrome P450 3A5Homo sapiens (human)
aromatase activityCytochrome P450 3A5Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
iron ion bindingCytochrome P450 2A7Homo sapiens (human)
oxygen bindingCytochrome P450 2A7Homo sapiens (human)
aromatase activityCytochrome P450 2A7Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A7Homo sapiens (human)
heme bindingCytochrome P450 2A7Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A7Homo sapiens (human)
monooxygenase activityCytochrome P450 3A7Homo sapiens (human)
iron ion bindingCytochrome P450 3A7Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A7Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A7Homo sapiens (human)
oxygen bindingCytochrome P450 3A7Homo sapiens (human)
heme bindingCytochrome P450 3A7Homo sapiens (human)
all-trans retinoic acid 18-hydroxylase activityCytochrome P450 3A7Homo sapiens (human)
aromatase activityCytochrome P450 3A7Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A7Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A7Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A7Homo sapiens (human)
monooxygenase activityCytochrome P450 2F1Homo sapiens (human)
iron ion bindingCytochrome P450 2F1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2F1Homo sapiens (human)
oxygen bindingCytochrome P450 2F1Homo sapiens (human)
aromatase activityCytochrome P450 2F1Homo sapiens (human)
heme bindingCytochrome P450 2F1Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2F1Homo sapiens (human)
monooxygenase activityCytochrome P450 2C18Homo sapiens (human)
iron ion bindingCytochrome P450 2C18Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C18Homo sapiens (human)
oxygen bindingCytochrome P450 2C18Homo sapiens (human)
aromatase activityCytochrome P450 2C18Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2C18Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C18Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C18Homo sapiens (human)
heme bindingCytochrome P450 2C18Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
monooxygenase activityCytochrome P450 4F2Homo sapiens (human)
iron ion bindingCytochrome P450 4F2Homo sapiens (human)
protein bindingCytochrome P450 4F2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 4F2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 4F2Homo sapiens (human)
alkane 1-monooxygenase activityCytochrome P450 4F2Homo sapiens (human)
heme bindingCytochrome P450 4F2Homo sapiens (human)
leukotriene-B4 20-monooxygenase activityCytochrome P450 4F2Homo sapiens (human)
arachidonic acid omega-hydroxylase activityCytochrome P450 4F2Homo sapiens (human)
alpha-tocopherol omega-hydroxylase activityCytochrome P450 4F2Homo sapiens (human)
tocotrienol omega-hydroxylase activityCytochrome P450 4F2Homo sapiens (human)
aromatase activityCytochrome P450 4F2Homo sapiens (human)
20-hydroxy-leukotriene B4 omega oxidase activityCytochrome P450 4F2Homo sapiens (human)
20-aldehyde-leukotriene B4 20-monooxygenase activityCytochrome P450 4F2Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 4F2Homo sapiens (human)
monooxygenase activityCytochrome P450 4F8Homo sapiens (human)
iron ion bindingCytochrome P450 4F8Homo sapiens (human)
alkane 1-monooxygenase activityCytochrome P450 4F8Homo sapiens (human)
heme bindingCytochrome P450 4F8Homo sapiens (human)
aromatase activityCytochrome P450 4F8Homo sapiens (human)
monooxygenase activityCytochrome P450 4A11Homo sapiens (human)
iron ion bindingCytochrome P450 4A11Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 4A11Homo sapiens (human)
alkane 1-monooxygenase activityCytochrome P450 4A11Homo sapiens (human)
heme bindingCytochrome P450 4A11Homo sapiens (human)
leukotriene-B4 20-monooxygenase activityCytochrome P450 4A11Homo sapiens (human)
aromatase activityCytochrome P450 4A11Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 4A11Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 4A11Homo sapiens (human)
monooxygenase activityCytochrome P450 4F3Homo sapiens (human)
iron ion bindingCytochrome P450 4F3Homo sapiens (human)
heme bindingCytochrome P450 4F3Homo sapiens (human)
leukotriene-B4 20-monooxygenase activityCytochrome P450 4F3Homo sapiens (human)
aromatase activityCytochrome P450 4F3Homo sapiens (human)
20-hydroxy-leukotriene B4 omega oxidase activityCytochrome P450 4F3Homo sapiens (human)
20-aldehyde-leukotriene B4 20-monooxygenase activityCytochrome P450 4F3Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
monooxygenase activityCytochrome P450 2A13Homo sapiens (human)
iron ion bindingCytochrome P450 2A13Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A13Homo sapiens (human)
heme bindingCytochrome P450 2A13Homo sapiens (human)
aromatase activityCytochrome P450 2A13Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A13Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A13Homo sapiens (human)
arachidonic acid omega-hydroxylase activityCytochrome P450 4A22Homo sapiens (human)
iron ion bindingCytochrome P450 4A22Homo sapiens (human)
heme bindingCytochrome P450 4A22Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 4A22Homo sapiens (human)
16-hydroxypalmitate dehydrogenase activityCytochrome P450 4A22Homo sapiens (human)
medium-chain fatty acid omega-hydroxylase activityCytochrome P450 4A22Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 4A22Homo sapiens (human)
alkane 1-monooxygenase activityCytochrome P450 4A22Homo sapiens (human)
iron ion bindingVitamin D 25-hydroxylaseHomo sapiens (human)
heme bindingVitamin D 25-hydroxylaseHomo sapiens (human)
vitamin D3 25-hydroxylase activityVitamin D 25-hydroxylaseHomo sapiens (human)
protein homodimerization activityVitamin D 25-hydroxylaseHomo sapiens (human)
D3 vitamins bindingVitamin D 25-hydroxylaseHomo sapiens (human)
steroid hydroxylase activityVitamin D 25-hydroxylaseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenVitamin D 25-hydroxylaseHomo sapiens (human)
monooxygenase activityCytochrome P450 2U1Homo sapiens (human)
iron ion bindingCytochrome P450 2U1Homo sapiens (human)
arachidonic acid omega-hydroxylase activityCytochrome P450 2U1Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 2U1Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2U1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2U1Homo sapiens (human)
heme bindingCytochrome P450 2U1Homo sapiens (human)
retinoic acid bindingCytochrome P450 2W1Homo sapiens (human)
monooxygenase activityCytochrome P450 2W1Homo sapiens (human)
all-trans retinal bindingCytochrome P450 2W1Homo sapiens (human)
iron ion bindingCytochrome P450 2W1Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2W1Homo sapiens (human)
all-trans-retinol bindingCytochrome P450 2W1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2W1Homo sapiens (human)
heme bindingCytochrome P450 2W1Homo sapiens (human)
monooxygenase activityCytochrome P450 2S1Homo sapiens (human)
thromboxane-A synthase activityCytochrome P450 2S1Homo sapiens (human)
iron ion bindingCytochrome P450 2S1Homo sapiens (human)
protein bindingCytochrome P450 2S1Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2S1Homo sapiens (human)
hydro-lyase activityCytochrome P450 2S1Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activityCytochrome P450 2S1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 2S1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2S1Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2S1Homo sapiens (human)
heme bindingCytochrome P450 2S1Homo sapiens (human)
monooxygenase activityCytochrome P450 3A43 Homo sapiens (human)
iron ion bindingCytochrome P450 3A43 Homo sapiens (human)
heme bindingCytochrome P450 3A43 Homo sapiens (human)
aromatase activityCytochrome P450 3A43 Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A43 Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A43 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
mitochondrial inner membraneCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
mitochondrial inner membraneCytochrome P450 2E1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2E1Homo sapiens (human)
cytoplasmCytochrome P450 2E1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2E1Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A6Homo sapiens (human)
cytoplasmic microtubuleCytochrome P450 2A6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A6Homo sapiens (human)
cytoplasmCytochrome P450 2A6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 4B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2B6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2B6Homo sapiens (human)
cytoplasmCytochrome P450 2B6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A5Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A5Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A7Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A7Homo sapiens (human)
cytoplasmCytochrome P450 2A7Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A7Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2F1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2F1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2F1Homo sapiens (human)
cytoplasmCytochrome P450 2F1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C18Homo sapiens (human)
plasma membraneCytochrome P450 2C18Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C18Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C18Homo sapiens (human)
cytoplasmCytochrome P450 2C18Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 4F2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 4F2Homo sapiens (human)
apical plasma membraneCytochrome P450 4F2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 4F2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 4F8Homo sapiens (human)
cytoplasmCytochrome P450 4A11Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 4A11Homo sapiens (human)
apical plasma membraneCytochrome P450 4A11Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 4A11Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 4A11Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 4F3Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A13Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A13Homo sapiens (human)
cytoplasmCytochrome P450 2A13Homo sapiens (human)
extracellular spaceCytochrome P450 4A22Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 4A22Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 4A22Homo sapiens (human)
endoplasmic reticulum membraneVitamin D 25-hydroxylaseHomo sapiens (human)
intracellular membrane-bounded organelleVitamin D 25-hydroxylaseHomo sapiens (human)
cytoplasmVitamin D 25-hydroxylaseHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 2U1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2U1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2U1Homo sapiens (human)
cytoplasmCytochrome P450 2U1Homo sapiens (human)
endoplasmic reticulum lumenCytochrome P450 2W1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2W1Homo sapiens (human)
plasma membraneCytochrome P450 2W1Homo sapiens (human)
cell surfaceCytochrome P450 2W1Homo sapiens (human)
cytoplasmCytochrome P450 2W1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2W1Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2S1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2S1Homo sapiens (human)
cytoplasmCytochrome P450 2S1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2S1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A43 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (119)

Assay IDTitleYearJournalArticle
AID673158Cytotoxicity against human 293T cells2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731950Ratio of IC50 for CARL L1073Q mutant in multidrug-resistant Plasmodium falciparum to IC50 for wild type CARL in multidrug-resistant Plasmodium falciparum Dd22021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673148Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in NMRI mouse assessed as increase of mouse survival at 100 mg/kg, po administered 24 hrs post infection (Rvb = 6 to 7 days)2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673175Tmax in Wistar rat at 30 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731954Ratio of IC50 for CARL L1108W mutant in multidrug-resistant Plasmodium falciparum to IC50 for wild type CARL in multidrug-resistant Plasmodium falciparum Dd22021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID1731928Oral bioavailability in Balb/c mouse at 10 mg/kg measured upto 24 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID1579722Volume of distribution at steady state in Wistar Hannover rat at 3 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID673169Half life in Wistar rat at 3 mg/kg, iv2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1579738Half life in human infected with Plasmodium vivax at 400 mg administered for 3 consecutive days and measured up to 192 hrs2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID1579740Antimalarial activity against Plasmodium falciparum infected in human assessed as median parasite clearance time at 800 mg/kg, po and measured on day 52019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID673280Oral bioavailability in Wistar rat at 100 mg/kg2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1579726Oral bioavailability in Wistar Hannover rat at 10 mg/kg by LC-MS/MS analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID1731929Intrinsic clearance in Balb/c mouse at 3 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673125Antimalarial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green fluorescence assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673159Cytotoxicity against mouse BA/F3 cells2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673146Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in po dosed NMRI mouse assessed as reduction of parasite level in blood administered 24 hrs post infection measured after 72 hrs post infection by flow cytometry2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1579732Half life in human at 10 to 1200 mg and measured up to 360 hrs by LC-MS/MS method2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID1731901Antiplasmodial activity against multidrug-sensitive Plasmodium falciparum NF54 transfected with GFP-Luc infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation pretreated for 48 hrs followed by [3H]-hypoxanthine addition me2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID1849708Inhibition of human ERG2021European journal of medicinal chemistry, Jan-15, Volume: 210An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.
AID673278Oral bioavailability in Wistar rat at 10 mg/kg2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673132Apparent permeability across apical to basolateral side in human Caco2 cells by LC/MS analysis2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731942Binding affinity to CARL L1073Q mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673167Volume of distribution in Wistar rat at 3 mg/kg, iv2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673174Tmax in Wistar rat at 10 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1579739Antimalarial activity against Plasmodium falciparum infected in human assessed as median parasite clearance time at 400 mg/kg, po administered for 3 consecutive day and measured on day 52019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID673276AUC (all) in Wistar rat at 30 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673285Selectivity index, ratio of CC50 for human HeLa cells to EC50 for Plasmodium falciparum2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673129Metabolic stability in human liver microsomes assessed as hepatic extraction ratio by LC/MS/MS analysis in presence of CYP2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673157Inhibition of human CYP3A42012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673282Selectivity index, ratio of CC50 for mouse BA/F3 cells to EC50 for Plasmodium falciparum2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731947Binding affinity to CARL M1050I mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673137AUC (0 to 24 hrs) in Balb/c mouse at 5 mg/kg, iv2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673275AUC (all) in Wistar rat at 10 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1579718Antimalarial activity against Plasmodium vivax assessed as reduction in parasite growth after 72 hrs by SYBR-green based fluorescence assay2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID1731955Ratio of IC50 for CARL V1053G mutant in multidrug-resistant Plasmodium falciparum to IC50 for wild type CARL in multidrug-resistant Plasmodium falciparum Dd22021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID1731933Protein binding in human plasma2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID1849716Antimalarial activity against Plasmodium falciparum 3D72021European journal of medicinal chemistry, Jan-15, Volume: 210An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.
AID1579733Inhibition of CYP3A4 (unknown origin)2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID673163Cytotoxicity against human HuH7 cells2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731932Ratio of unbound average drug concentration in Balb/c mouse at 20 mg/kg, po to IC50 for antiplasmodial activity against multidrug-sensitive Plasmodium falciparum NF542021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673152Dose normalized AUC (0 to 5 hrs) in Wistar rat at 10 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673155Inhibition of human CYP2C92012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673273Half life in Wistar rat at 30 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673168Clearance in Wistar rat at 3 mg/kg, iv2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673143Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in NMRI mouse assessed as reduction of parasite level in blood at 30 mg/kg, po administered 24 hrs post infection measured after 72 hrs post infection by flow cytometry2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1849700Dissociation constant, pKa of compound2021European journal of medicinal chemistry, Jan-15, Volume: 210An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.
AID1731931Unbound average drug concentration in Balb/c mouse at 20 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673150AUC (0 to 5 hrs) in Wistar rat at 10 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731945Binding affinity to CARL L1108W mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673284Selectivity index, ratio of CC50 for human HepG2 cells to EC50 for Plasmodium falciparum2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673139Tmax in Balb/c mouse at 20 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731943Binding affinity to CARL A1122E mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673124Antimalarial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green fluorescence assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673160Cytotoxicity against CHO cells2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673144Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in NMRI mouse assessed as reduction of parasite level in blood at 100 mg/kg, po administered 24 hrs post infection measured after 72 hrs post infection by flow cytometry2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673274Half life in Wistar rat at 100 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731956Ratio of IC50 for CARL M1050I mutant in multidrug-resistant Plasmodium falciparum to IC50 for wild type CARL in multidrug-resistant Plasmodium falciparum Dd22021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673147Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in NMRI mouse assessed as increase of mouse survival at 30 mg/kg, po administered 24 hrs post infection (Rvb = 6 to 7 days)2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731957Ratio of IC50 for CARL I1139K mutant in multidrug-resistant Plasmodium falciparum to IC50 for wild type CARL in multidrug-resistant Plasmodium falciparum Dd22021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673151Cmax in Wistar rat at 10 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673156Inhibition of human CYP2D62012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1579741Antimalarial activity against Plasmodium vivax infected in human assessed as median parasite clearance time at 400 mg/kg, po administered for 3 consecutive day and measured on day 52019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID673145Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in NMRI mouse assessed as reduction of parasite level in blood at 30 mg/kg, po administered 24 hrs post infection qd for 3 days measured after 96 hrs post infection by flow cyto2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1579728Cmax in human at 10 to 1200 mg and measured up to 360 hrs by LC-MS/MS method2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID1579719Antimalarial activity against Plasmodium falciparum assessed as reduction in parasite growth after 72 hrs by SYBR-green based fluorescence assay2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID1579736Cardiotoxicity in human assessed as effect on QT parameters at 800 mg in presence of PPQ2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID673141AUC (0 to 24 hrs) in Balb/c mouse at 20 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673281Selectivity index, ratio of CC50 for human 293T cells to EC50 for Plasmodium falciparum2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1579731Volume of distribution in human at 10 to 1200 mg and measured up to 360 hrs by LC-MS/MS method2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID1579720Half life in Wistar Hannover rat at 3 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID1579737Half life in human infected with Plasmodium falciparum at 400 mg administered for 3 consecutive days and measured up to 192 hrs2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID673135Clearance in Balb/c mouse plasma at 5 mg/kg, iv2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731953Ratio of IC50 for CARL E1104K mutant in multidrug-resistant Plasmodium falciparum to IC50 for wild type CARL in multidrug-resistant Plasmodium falciparum Dd22021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673153Inhibition of human CYP1A22012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673134Volume of distribution in Balb/c mouse at 5 mg/kg, iv2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731952Ratio of IC50 for CARL 11072V mutant in multidrug-resistant Plasmodium falciparum to IC50 for wild type CARL in multidrug-resistant Plasmodium falciparum Dd22021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673161Cytotoxicity against human Hep2 cells2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731946Binding affinity to CARL V1053G mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID1731951Ratio of IC50 for CARL A1122E mutant in multidrug-resistant Plasmodium falciparum to IC50 for wild type CARL in multidrug-resistant Plasmodium falciparum Dd22021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673138Cmax in Balb/c mouse at 20 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731925Blood clearance in Balb/c mouse at 3 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673142Oral bioavailability in Balb/c mouse at 20 mg/kg2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673154Inhibition of human CYP2C192012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731944Binding affinity to CARL 11072V mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673272Half life in Wistar rat at 10 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673127Metabolic stability in mouse liver microsomes assessed as hepatic extraction ratio by LC/MS/MS analysis in presence of CYP2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673283Selectivity index, ratio of CC50 for CHO cells to EC50 for Plasmodium falciparum2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1849707Inhibition of CYP450 (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.
AID1731948Binding affinity to CARL I1139K mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID1731949Binding affinity to CARL E1104K mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID1579742Antimalarial activity against Plasmodium vivax infected in human assessed as median parasite clearance time at 800 mg/kg, po and measured on day 52019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID1731930Unbound AUC in Balb/c mouse at 20 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID1579723Cmax in Wistar Hannover rat at 10 mg/kg, po by LC-MS/MS analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID673279Oral bioavailability in Wistar rat at 30 mg/kg2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673149Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in NMRI mouse assessed as increase of mouse survival at 30 mg/kg, po administered 24 hrs post infection qd for 3 days (Rvb = 6 to 7 days)2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673176Tmax in Wistar rat at 100 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1579721Plasma clearance in Wistar Hannover rat at 3 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID1579727Tmax in human at 10 to 1200 mg and measured up to 360 hrs by LC-MS/MS method2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID673173Cmax in Wistar rat at 100 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673133Apparent permeability across basolateral to apical side in human Caco2 cells by LC/MS analysis2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1579730Apparent clearance in human at 10 to 1200 mg and measured up to 360 hrs by LC-MS/MS method2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID673171Cmax in Wistar rat at 10 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673136Half life in Balb/c mouse at 5 mg/kg, iv2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673162Cytotoxicity against human HeLa cells2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1849722In vivo antimalarial activity against Plasmodium berghei infected in mouse model2021European journal of medicinal chemistry, Jan-15, Volume: 210An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.
AID673277AUC (all) in Wistar rat at 100 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1579734Cardiotoxicity in human assessed as effect on QT parameters at 800 mg2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID673172Cmax in Wistar rat at 30 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID673170AUC in Wistar rat at 3 mg/kg, iv2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1731941Binding affinity to wild type CARL in multidrug-resistant Plasmodium falciparum Dd2 infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite
AID673131Permeability of the compound by PAMPA2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1579725Half life in Wistar Hannover rat at 10 mg/kg, po by LC-MS/MS analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID673130Inhibition of human ERG channel expressed in CHO cells by patch clamp assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1579724Tmax in Wistar Hannover rat at 10 mg/kg, po by LC-MS/MS analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID673286Selectivity index, ratio of CC50 for human HuH7 cells to EC50 for Plasmodium falciparum2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1579729AUC (0 to 24 hrs) in human at 10 to 1200 mg and measured up to 360 hrs by LC-MS/MS method2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID673140Half life in Balb/c mouse at 20 mg/kg, po2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1849721Antimalarial activity against Plasmodium falciparum W22021European journal of medicinal chemistry, Jan-15, Volume: 210An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.
AID673128Metabolic stability in rat liver microsomes assessed as hepatic extraction ratio by LC/MS/MS analysis in presence of CYP2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (62.50)24.3611
2020's6 (37.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.29 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index27.81 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (31.25%)5.53%
Reviews5 (31.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (37.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		3.6420aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
primaquine
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.		3.4110aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
pamaquine
pamaquine: structure; RN given refers to parent cpd		3.4110aminoquinoline
pentaquine
pentaquine: RN given refers to parent cpd		3.4110
mefloquine
(-)-(11S,2'R)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown.		3.3110[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolantimalarial
artemisinin
(+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		3.2710organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
artemether
Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		3.9911artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid		antimalarial
quinocide
quinocide: Russian drug; RN given refers to parent cpd; structure		3.4110
coptisine
coptisine: RN given refers to parent cpd		3.4110alkaloidmetabolite
tafenoquine
tafenoquine : A racemate comprising equimolar amounts of (R)- and (S)-tafenoquine.. N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine : An aminoquinoline that is 8-aminoquinoline which is substituted by methoxy groups at positions 2 and 6, a methyl group at position 4, and a m-(trifluoromethyl)phenoxy group at position 5, and in which the amino substituent at position 8 is itself substituted by a 5-aminopentan-2-yl group.		3.2710(trifluoromethyl)benzenes;
aminoquinoline;
aromatic ether;
primary amino compound;
secondary amino compound
piperaquine
piperaquine : An aminoquinoline that is 1,3-di(piperazin-1-yl)propane in which the nitrogen at position 4 of each of the piperazine moieties is replaced by a 7-chloroquinolin-4-yl group.		10.0821aminoquinoline;
N-arylpiperazine;
organochlorine compound		antimalarial
lumefantrine
Lumefantrine: A fluorene derivative that is used in combination with ARTEMETHER for the treatment of MALARIA (see ARTEMETHER-LUMEFANTRINE DRUG COMBINATION).. lumefantrine : A member of the class of fluorenes that is 9-(p-chlorobenzylidene)-9H-fluorene which is substitutec by chlorine at positions 2 and 7, and by a 2-(dibutylamino)-1-hydroxyethyl group at position 4. An antimalarial drug used in combination with artemether for the treatment of multi-drug resistant strains of falciparum malaria.		11.1941fluorenes;
monochlorobenzenes;
secondary alcohol;
tertiary amine		antimalarial
artesunate
artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether		2.0710artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
oz 439
artefenomel: an antimalarial ozonide; structure in first source		4.2720
nitd 609
NITD 609: an antimalarial and coccidiostat; structure in first source		5.0840
6-chloro-7-methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl)quinolin-4(1h)-one
6-Chloro-7-methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl)quinolin-4(1H)-one: structure in first source		3.4110
ferroquine
ferroquine: an antimalarial agent; structure in first source		3.2710
ConditionIndicatedRelationship StrengthStudiesTrials
Plasmodium falciparum Malaria
[description not available]		012.1263
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		19.1263
Infections, Plasmodium
[description not available]		07.6572
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		19.6572
Adverse Drug Event
[description not available]		03.5611
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		03.5611
Pyrexia
[description not available]		04.4311
Plasmodium vivax Malaria
[description not available]		04.4311
Fever
An abnormal elevation of body temperature, usually as a result of a pathologic process.		04.4311
Malaria, Vivax
Malaria caused by PLASMODIUM VIVAX. This form of malaria is less severe than MALARIA, FALCIPARUM, but there is a higher probability for relapses to occur. Febrile paroxysms often occur every other day.		04.4311